Are Circulating Cytokines Reliable Biomarkers for Amyotrophic Lateral Sclerosis?

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2019 Jun 15

PMID 31195629

Citations 24

Authors

Laura Moreno-Martinez

Ana Cristina Calvo

Maria Jesus Munoz

Rosario Osta

Affiliations

Soon will be listed here.

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that has no effective treatment. The lack of any specific biomarker that can help in the diagnosis or prognosis of ALS has made the identification of biomarkers an urgent challenge. Multiple panels have shown alterations in levels of numerous cytokines in ALS, supporting the contribution of neuroinflammation to the progressive motor neuron loss. However, none of them is fully sensitive and specific enough to become a universal biomarker for ALS. This review gathers the numerous circulating cytokines that have been found dysregulated in both ALS animal models and patients. Particularly, it highlights the opposing results found in the literature to date, and points out another potential application of inflammatory cytokines as therapeutic targets.

Citing Articles

Restoring Homeostasis: Treating Amyotrophic Lateral Sclerosis by Resolving Dynamic Regulatory Instability.

Lee A, Bi S, Ridgeway E, Al-Hussaini I, Deshpande S, Krueger A Int J Mol Sci. 2025; 26(3).

PMID: 39940644 PMC: 11817447. DOI: 10.3390/ijms26030872.

Blood diagnostic and prognostic biomarkers in amyotrophic lateral sclerosis.

Lv Y, Li H Neural Regen Res. 2024; 20(9):2556-2570.

PMID: 39314138 PMC: 11801290. DOI: 10.4103/NRR.NRR-D-24-00286.

Inflammatory signature in amyotrophic lateral sclerosis predicting disease progression.

Femiano C, Bruno A, Gilio L, Buttari F, Dolcetti E, Galifi G Sci Rep. 2024; 14(1):19796.

PMID: 39187524 PMC: 11347586. DOI: 10.1038/s41598-024-67165-9.

A Potential Role of Interleukin-5 in the Pathogenesis and Progression of Amyotrophic Lateral Sclerosis: A New Molecular Perspective.

Motataianu A, Andone S, Stoian A, Balasa R, Hutanu A, Sarmasan E Int J Mol Sci. 2024; 25(7).

PMID: 38612591 PMC: 11011909. DOI: 10.3390/ijms25073782.

Developing a novel immune infiltration-associated mitophagy prediction model for amyotrophic lateral sclerosis using bioinformatics strategies.

Du R, Chen P, Li M, Zhu Y, He Z, Huang X Front Immunol. 2024; 15:1360527.

PMID: 38601155 PMC: 11005030. DOI: 10.3389/fimmu.2024.1360527.

References

Cedarbaum J, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B . The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999; 169(1-2):13-21. DOI: 10.1016/s0022-510x(99)00210-5. View

Niebroj-Dobosz I, Janik P, Kwiecinski H . Effect of Riluzole on serum amino acids in patients with amyotrophic lateral sclerosis. Acta Neurol Scand. 2002; 106(1):39-43. DOI: 10.1034/j.1600-0404.2002.00206.x. View

Devos D, Moreau C, Lassalle P, Perez T, De Seze J, Brunaud-Danel V . Low levels of the vascular endothelial growth factor in CSF from early ALS patients. Neurology. 2004; 62(11):2127-9. DOI: 10.1212/01.wnl.0000129913.44351.a3. View

Moreau C, Devos D, Brunaud-Danel V, Defebvre L, Perez T, Destee A . Elevated IL-6 and TNF-alpha levels in patients with ALS: inflammation or hypoxia?. Neurology. 2005; 65(12):1958-60. DOI: 10.1212/01.wnl.0000188907.97339.76. View

Kiaei M, Petri S, Kipiani K, Gardian G, Choi D, Chen J . Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci. 2006; 26(9):2467-73. PMC: 6793668. DOI: 10.1523/JNEUROSCI.5253-05.2006. View

Shi N, Kawano Y, Tateishi T, Kikuchi H, Osoegawa M, Ohyagi Y . Increased IL-13-producing T cells in ALS: positive correlations with disease severity and progression rate. J Neuroimmunol. 2006; 182(1-2):232-5. DOI: 10.1016/j.jneuroim.2006.10.001. View

Andreadou E, Kapaki E, Kokotis P, Paraskevas G, Katsaros N, Libitaki G . Plasma glutamate and glycine levels in patients with amyotrophic lateral sclerosis: the effect of riluzole treatment. Clin Neurol Neurosurg. 2007; 110(3):222-6. DOI: 10.1016/j.clineuro.2007.10.018. View

Mitchell R, Freeman W, Randazzo W, Stephens H, Beard J, Simmons Z . A CSF biomarker panel for identification of patients with amyotrophic lateral sclerosis. Neurology. 2008; 72(1):14-9. DOI: 10.1212/01.wnl.0000333251.36681.a5. View

Turner M, Kiernan M, Leigh P, Talbot K . Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol. 2008; 8(1):94-109. DOI: 10.1016/S1474-4422(08)70293-X. View

10.

Kuhle J, Lindberg R, Regeniter A, Mehling M, Steck A, Kappos L . Increased levels of inflammatory chemokines in amyotrophic lateral sclerosis. Eur J Neurol. 2009; 16(6):771-4. DOI: 10.1111/j.1468-1331.2009.02560.x. View

11.

Neymotin A, Petri S, Calingasan N, Wille E, Schafer P, Stewart C . Lenalidomide (Revlimid) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis. Exp Neurol. 2009; 220(1):191-7. PMC: 3979314. DOI: 10.1016/j.expneurol.2009.08.028. View

12.

Stommel E, Cohen J, Fadul C, Cogbill C, Graber D, Kingman L . Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: a phase II open label clinical trial. Amyotroph Lateral Scler. 2009; 10(5-6):393-404. PMC: 3820489. DOI: 10.3109/17482960802709416. View

13.

Glass C, Saijo K, Winner B, Marchetto M, Gage F . Mechanisms underlying inflammation in neurodegeneration. Cell. 2010; 140(6):918-34. PMC: 2873093. DOI: 10.1016/j.cell.2010.02.016. View

14.

Tateishi T, Yamasaki R, Tanaka M, Matsushita T, Kikuchi H, Isobe N . CSF chemokine alterations related to the clinical course of amyotrophic lateral sclerosis. J Neuroimmunol. 2010; 222(1-2):76-81. DOI: 10.1016/j.jneuroim.2010.03.004. View

15.

Mitchell R, Simmons Z, Beard J, Stephens H, Connor J . Plasma biomarkers associated with ALS and their relationship to iron homeostasis. Muscle Nerve. 2010; 42(1):95-103. DOI: 10.1002/mus.21625. View

16.

Fiala M, Chattopadhay M, La Cava A, Tse E, Liu G, Lourenco E . IL-17A is increased in the serum and in spinal cord CD8 and mast cells of ALS patients. J Neuroinflammation. 2010; 7:76. PMC: 2992053. DOI: 10.1186/1742-2094-7-76. View

17.

Beers D, Henkel J, Zhao W, Wang J, Huang A, Wen S . Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis. Brain. 2011; 134(Pt 5):1293-314. PMC: 3097891. DOI: 10.1093/brain/awr074. View

18.

Pollari E, Savchenko E, Jaronen M, Kanninen K, Malm T, Wojciechowski S . Granulocyte colony stimulating factor attenuates inflammation in a mouse model of amyotrophic lateral sclerosis. J Neuroinflammation. 2011; 8:74. PMC: 3146845. DOI: 10.1186/1742-2094-8-74. View

19.

Otto M, Bowser R, Turner M, Berry J, Brettschneider J, Connor J . Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS. Amyotroph Lateral Scler. 2012; 13(1):1-10. DOI: 10.3109/17482968.2011.627589. View

20.

Tarasiuk J, Kulakowska A, Drozdowski W, Kornhuber J, Lewczuk P . CSF markers in amyotrophic lateral sclerosis. J Neural Transm (Vienna). 2012; 119(7):747-57. DOI: 10.1007/s00702-012-0806-y. View